The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Jones David Scott since 2020.
This trader's CIK number is 1779458.
At the time of last reporting, Jones David Scott was the SVP & Chief Commercial Officer of Eyepoint Pharmaceuticals, Inc.. (stock ticker symbol EYPT).
Also see all insider trading activities at Eyepoint Pharmaceuticals, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2024 | EYPT | 0 | $0 | 73,192 | $1,753,305 | 98,444 | $685,030 |
| 2023 | EYPT | 0 | $0 | 0 | $0 | 9,967 | $0 |
| 2022 | EYPT | 0 | $0 | 0 | $0 | 4,105 | $0 |
| 2021 | EYPT | 0 | $0 | 0 | $0 | 4,105 | $0 |
| 2020 | EYPT | 0 | $0 | 0 | $0 | 41,050 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-02-09 | EYPT | Option Ex | 9,967 | .00 | 0 |
| 2024-02-02 | EYPT | Option Ex | 209 | 11.47 | 2,397 |
| 2024-02-02 | EYPT | Sale | 209 | 28.49 | 5,954 |
| 2024-01-26 | EYPT | Option Ex | 26,017 | 8.08 | 210,217 |
| 2024-01-26 | EYPT | Sale | 26,017 | 25.36 | 659,791 |
| 2024-01-24 | EYPT | Option Ex | 11,300 | 8.08 | 91,304 |
| 2024-01-25 | EYPT | Option Ex | 600 | 8.08 | 4,848 |
| 2024-01-24 | EYPT | Sale | 11,300 | 25.01 | 282,624 |
| 2024-01-25 | EYPT | Sale | 600 | 25.00 | 15,000 |
| 2024-01-22 | EYPT | Option Ex | 34,166 | 10.80 | 368,992 |
| 2024-01-23 | EYPT | Option Ex | 900 | 8.08 | 7,272 |
| 2024-01-22 | EYPT | Sale | 34,166 | 22.46 | 767,436 |
| 2024-01-23 | EYPT | Sale | 900 | 25.00 | 22,500 |
| 2024-01-06 | EYPT | Option Ex | 15,285 | .00 | 0 |
| 2023-02-09 | EYPT | Option Ex | 9,967 | .00 | 0 |
| 2022-02-28 | EYPT | Option Ex | 4,105 | .00 | 0 |
| 2021-02-28 | EYPT | Option Ex | 4,105 | .00 | 0 |
| 2020-06-30 | EYPT | Option Ex | 41,050 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Jones David Scott (SVP & Chief Commercial Officer of Eyepoint Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.